Of 1496 infants with weight data available at 6 months of age, 457 (31%) were exposed to tenofovir (Table 2). The median duration of TDF exposure among those exposed was 21.3 weeks. For infants exposed to TDF in this group, 66% were exposed in the first trimester and 72% were exposed for >12-week duration. Of the 61 infants with age- and sex-adjusted 6 month weight z-scores <fifth percentile, 38% were exposed to TDF in utero. The group of women with infants followed for 6 months was not different than the entire group with infant birth weight available with respect to measured demographic and clinical information.
Although we feel it may not be clinically significant, the isolated finding of lower age- and sex-adjusted weight z-score of <fifth percentile at 6 months of age in infants of women who initiated TDF in the second or third trimester should not be completely overlooked. There are several studies in humans that suggest a delay in effect from ARV exposure not occurring until several months to years after exposure. For instance, febrile seizures were significantly more common in ARV-exposed compared with ARV-unexposed HIV-exposed infants; this effect did not seem until 6–12 months of age.16 In the Women and Infants Transmission Study, the significant difference in CD8+ cell counts by ARV exposure did not seem until 6–24 months.17 In the SMARTTs trial, data at 1 year but not at birth demonstrated lower mean length-for-age and head-circumference-for-age z-scores associated with maternal TDF use.6 More encouraging are results from the Development of AntiRetroviral Therapy in Africa trial,13 which recently reported no evidence that TDF effects growth of infants up to 2 years of age, in a cohort of 226 live births. The clinical relevance and underlying biologic mechanisms of this finding in our study are uncertain. Long-term studies are needed to determine whether this short-term effect on growth has any long lasting impact in childhood or adult life.
Our study has several strengths. We had a large sample size, with large (31%) proportion of infants having tenofovir exposure. In addition, we were able to examine growth in several different ways (absolute weight, underweight, and small for gestational age). We were also able to examine tenofovir exposure by several different measures, to determine if exposure in the first trimester had an effect or if cumulative dose of tenofovir had an effect. Neither seems to have affected fetal or infant growth.
Like any cohort study, there is potential for selection bias in the nonrandom allocation of women to TDF as part of their multiagent HAART. In addition, more women exposed to TDF were on a PI containing HAART regimen than those not exposed to TDF, which may lead to confounding in results. Approximately 26% of the infants with birth weight available do not have available 6-month weight values to study. In addition, we were not able to examine growth beyond 6 months. Another limitation is that we only examined growth as a function of weight and not length or head circumference. We recognize this is an important limitation, especially in light of findings from the SMARTT study demonstrating adverse effects on length-for age and head-circumference-for-age z-scores at 1 year,6 despite no observed difference in growth measurements at birth. We also do not have data on maternal adherence to drug therapy, and thus true fetal exposure. Current guidelines from the Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission assign TDF as an alternate agent (not first line) for the treatment of acute HIV infection in pregnant women, whereas it is considered first line treatment in other groups. The need for long-term data on TDF is vital given the rising use in a pregnant population. Long-term growth and developmental outcomes are still needed in children exposed to tenofovir in future large cohorts. There are many challenges to obtaining long-term safety data on drugs used to treat HIV in pregnancy. This population has many socioeconomic and cultural barriers to seeking and maintaining care, there is difficulty in monitoring drug adherence, and this group is often exposed to multiple drug regimens. Although we acknowledge that 45% of TDF-exposed infants were also co-enrolled in the SMARTT study,6 we feel our study still significantly contributes to the literature on this population given the sparse literature on the topic, the challenges to obtaining this information, and the growing use of TDF in clinical obstetric practice. The results of our study present an overall reassuring picture for both fetal growth and neonatal growth as reflected by weight in neonates exposed to TDF in pregnancy. Future studies should be designed to focus on rare neonatal outcomes (fracture, neutropenia, etc.) and long-term delayed effects on infant growth.
P1025 Team Acknowledgment: R. Tuomala, MD, Brigham and Women's Hospital, Boston, MA; E. Smith, MD, National Institute of Allergy and Infectious Diseases Division of AIDS, Pediatric Medicine Branch, Bethesda, MD; K. M. Oden, MHS, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Silver Spring, MD; D. Kacanek, ScD, Harvard School of Public Health, Boston, MA; E. Leister, MS, Harvard School of Public Health, Boston, MA; D. E. Shapiro, PhD, Harvard School of Public Health, Boston, MA; E. A. Barr, CPNP, CNM, MSN, University of Colorado Denver, The Children's Hospital, Denver, CO; D. W. Wara, MD, University of California at San Francisco, San Francisco, CA; A. Bardeguez, MD, MPH, FACOG, University of Medicine and Dentistry of New Jersey, Newark, NJ; S. K. Burchett, MD, MSc, Harvard Medical School, Boston, MA; J. Guiterrez, MD, Bronx-Lebanon Hospital, Bronx, NY; K. Malee, PhD, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; A. M. Stek, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA; P. Tanjutco, MD, Washington Hospital Center, WA, DC; Y. Bryson, MD, David Geffen School of Medicine, University of California, Los Angeles, CA; M. T. Basar, BS, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; A. Hernandez, MA, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; A. Jennings, BS, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; T. R. Cressey, PhD, BSc, Program for HIV Prevention & Treatment, Chang Mai, Thailand; J. Bryant, MPA, Westat, Rockville, MD.
Obstetrics Site Support: 2802 NJ Medical School Clinical Research Site (CRS) (A. D. Bardeguez, MD, MPH; L. Bettica, RN; C. Calilap-Bernardo, RN); 3601 University of California Los Angeles (UCLA)-Los Angeles, CA/Brazil AIDS Consortium (LABAC) CRS; 3801 Texas Children's Hospital CRS; 4001 Chicago Children's CRS; 4101 Columbia IMPAACT CRS (A. Higgins, RN; G. Silva, RN; S. Gaddipati, MD); 4201 University of Miami Pediatric/Perinatal HIV/AIDS CRS (S. Yasin, MD, C. Mitchell, MD, S. Lo Wong, MD, P. Bryan, RN); 4601 University California, San Diego Maternal, Child, and Adolescent HIV CRS (S. A. Spector, MD; A. Hull, MD; M. Caffery, RN, MSN; J. Manning, RN, BSN); 4701 Duke University Medical Center Pediatric CRS (E. Livingston, MD; M. Donnelly, PA; J. Wilson, RN; J. Giner, RN); 5003 Metropolitan Hospital NICHD CRS; 5009 Children's Hospital of Boston NICHD CRS (N. Karthas, RN, MS, CPNP; L. Tucker, BFA; A. Buck, RN; C. Kneut, RN, MS, CPNP); 5011 Boston Medical Center Pediatric HIV Program NICHD CRS; 5012 New York University NICHD CRS (S. Deygoo, MS; A. Kaul, MD; M. Minter, RN; S. Akleh, RN; Supported in part by Grant UL1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), National Institutes of Health); 5013 Jacobi Medical Center Bronx NICHD CRS; 5015 Children's National Medical Center WA DC NICHD CRS; 5017 Seattle Children's Hospital CRS (A. Robson; J. Hitti, MD; C. Venema-Weiss, CNM; A. Klastorin, MSW); 5018 University of South Florida, Tampa NICHD CRS (K. L. Bruder, MD; G. Lewis, RN; D. Casey, RN); 5023 Washington Hospital Center NICHD CRS (S. Parker, MD; R. Scott, MD; P. Tanjutco, MD; V. Emmanuel, BA); 5031 San Juan City Hospital PR NICHD CRS (A. Mimoso, MD; R. Diaz, MD; E. Perez; O. Pereira); 5040 State University of New York Stony Brook NICHD CRS (J. Griffin, NP; P. Ogburn, MD); 5041 Children's Hospital of Michigan NICHD CRS; 5044 Howard University Washington, DC, NICHD CRS; 5045 Harbor UCLA Medical Center NICHD CRS; 5048 University of Southern California, Los Angeles, CA, NICHD CRS (A. Stek, MD; F. Kramer, MD; L. Spencer, MD; A. Kovacs, MD); 5051 University of Florida College of Medicine, Jacksonville NICHD CRS (M. Rathore, MD; I. Delke, MD; G. Thomas, RN; B. Millwood, RN); 5052 University of Colorado, Denver NICHD CRS (A. Katai, MHA; T. Kennedy, FNP-BC; K. Kinzie, FNP-BC; J. Wallace, MSW; Supported by NIH/NCATS Colorado CTSI Grant UL1 TR000154); 5055 South Florida CDC, Ft Lauderdale NICHD CRS; 5083 Rush University Cook County Hospital, Chicago NICHD CRS (J. Schmidt, MD; H. Cejtin, MD; M. McNichols, RN, MSN, CCRC; J. Senka, RN); 5091 University of California, San Francisco NICHD CRS (D. Cohan, MD; This publication was supported by NIH/NCRR UCSF-CTSI Grant UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH); 5092 Johns Hopkins University, Baltimore NCHD CRS (J. Anderson, MD; E. Sheridan-Malone, RN); 5093 Miller Children's Hospital Long Beach, CA, NICHD CRS (C. Tolentino-Balbridge, RN; Janielle Jackson-Alvarez, RN; D. Michalik, DO; J. S. Batra, MD); 5094 University of Maryland Baltimore NICHD CRS (D. Watson, MD; M. Johnson, DDS; C. Hilyard); 5095 Tulane University, New Orleans NICHD CRS (R. Maupin, MD; C. Dola, MD; Y. Luster, RN; S. Bradford, RN); 5096 University of Alabama Birmingham NICHD CRS (A. Tita, MD; M. Parks, CRNP; S. Robbins, BA); 6501 St Jude/UTHSC CRS (E. Thorpe, Jr, MD; K. Knapp, MD; P. Finnie, MSN; N. Sublette, RN, PhD); 6601 University of Puerto Rico Pediatric HIV/AIDS Research Program CRS (C. D. Zorrilla, MD; V. Tamayo-Agrait, MD); 6701 The Children's Hospital of Philadelphia IMPAACT CRS; 6901 Bronx-Lebanon Hospital IMPAACT CRS (R. Wright, MD); 7301 WNE Maternal Pediatric Adolescent AIDS CRS (S. Cormier, RN; K. Luzuriaga, MD; Supported by CTSA Grant 8UL1TR000161).
1. Mother-to-child transmission
infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458–465.
2. Cooper ER, Charurat M, Mofenson L, et al.. Combination antiretroviral strategies for the treatment of pregnant HIV
-1-infected women and prevention of perinatal HIV
-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494.
3. Panel on Treatment of HIV
-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV
-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV
Transmission in the United States. Available at: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
. Accessed October 4, 2013.
6. Siberry GK, Williams PL, Mendez H, et al.. Safety of tenofovir
use during pregnancy
: early growth outcomes in HIV
-exposed uninfected infants. AIDS. 2012;26:1151–1159.
7. Nurutdinova D, Onen NF, Hayes E, et al.. Adverse effects of tenofovir
use in HIV
-infected pregnant women and their infants. Ann Pharmacother. 2008;42:1581–1585.
8. Eastwood KPK, Melvin A, Venema-Weiss C, et al.. effect of tenofovir
on viral suppression during pregnancy
-1 infected women. Am J Obstetrics Gynecol. 2009;2010:S233.
9. Carlevari MZS, Olmscheid B. Use of tenofovir
disoproxil fumarate (TDF
) and Emtricitabine (FTC) in pregnancy
: findings from the antiretroviral pregnancy
Registry (APR). Infection. 2009;37:96.
11. Hirt D, Urien S, Ekouevi DK, et al.. Population pharmacokinetics of tenofovir
-1-infected pregnant women and their neonates (ANRS 12109). Nature. 2009;85:182–189.
12. Kinai E, Hosokawa S, Gomibuchi H, et al.. Blunted fetal growth by tenofovir
in late pregnancy
. AIDS. 2012;26:2119–2120.
13. Gibb DM, Kizito H, Russell EC, et al.. Pregnancy
and infant outcomes among HIV
-infected women taking long-term ART with and without tenofovir
in the DART trial. PLoS Med. 2012;9:e1001217.
14. Olsen IE, Groveman SA, Lawson ML, et al.. New intrauterine growth curves based on United States data. Pediatrics. 2010;125:e214–224.
15. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al.. CDC growth charts: United States. Adv data. 2000;314:1–27.
16. Landreau-Mascaro A, Barret B, Mayaux MJ, et al.. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet. 2002;359:583–584.
17. Pacheco SE, McIntosh K, Lu M, et al.. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV
-uninfected children: an analysis of the women and infants transmission study. J Infect Dis. 2006;194:1089–1097.
18. Hussain S, Khayat A, Tolaymat A, et al.. Nephrotoxicity in a child with perinatal HIV
, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034–1036.
19. Karras A, Lafaurie M, Furco A, et al.. Tenofovir
-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–1073.
20. Peyriere H, Reynes J, Rouanet I, et al.. Renal tubular dysfunction associated with tenofovir
therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273.
21. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir
: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342–344.
22. Rifkin BS, Perazella MA. Tenofovir
-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–284.
23. Tarantal AF, Castillo A, Ekert JE, et al.. Fetal and maternal outcome after administration of tenofovir
to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 2002;29:207–220.
24. Tarantal AF, Marthas ML, Shaw JP, et al.. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:323–333.
25. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al.. Chronic administration of tenofovir
to rhesus macaques from infancy through adulthood and pregnancy
: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144–3160.